Retinitis pigmentosa
An inherited eye disease that slowly damages the retina, the light-sensing layer at the back of the eye. The first sign is usually a loss of night vision, which may occur in childhood or adolescence. Later, blind spots at the edges of the visual field increase in size until they merge to produce tunnel vision. There is no effective treatment for this condition, but clinical trials are in progress to assess new treatments, including gene therapy. It affects about 1 in 4,000 people in the United States. The disorder will continue to progress slowly, and complete blindness is uncommon.
Read more about retinitis pigmentosaTrial-stage treatments and research studies you can join
Filters
- NPI-001 to protect eye cells in retinitis pigmentosa linked to Usher syndrome
Tests NPI-001 against placebo in adults with Usher syndrome and retinitis pigmentosa.
Dallas, United StatesAge 18+ - Tests RTx-015 eye injection in adults with retinitis pigmentosa
Tests a single eye injection of a gene therapy in adults with retinitis pigmentosa.
‘Aiea, United StatesAlso Bakersfield, Beverly Hills, Bloomfield, Deerfield Beach, Detroit, Edina, Greensboro, Mt. Pleasant, …Age 18+ - Tests stem cell exosomes given by nose for optic nerve damage
Tests stem cell exosomes given into the nose in people with non-arteritic ischemic optic neuropathy.
Naples, United States - Tests OpCT-001 cell therapy safety in adults with inherited retinal disease
Tests a cell therapy injected under the retina in adults with retinitis pigmentosa.
Dallas, United StatesAlso Los Angeles, Madison, Miami, PhiladelphiaAge 18+ - Testing OCT-980 tablets in people with a genetic form of retinitis pigmentosa
Tests OCT-980 in healthy adults and adults with inherited retinitis pigmentosa.
Dallas, United StatesAlso PortlandAge 18+ - Tests disulfiram's effect on vision in people with retinal degeneration
Tests disulfiram on vision in adults with retinal disease who take it for alcohol use.
Rochester, United StatesAge 18+ - Tests an experimental antisense medicine for a rare inherited nerve and eye disease
Tests an experimental medicine in one person with a rare inherited disease.
Aurora, United States - Testing disulfiram to help vision in inherited retinal degeneration
Tests disulfiram against placebo in adults with inherited retinal degeneration.
Seattle, United StatesAge 18+ - Tests DSP-3077 cell-based retinal sheets in adults with retinitis pigmentosa
Tests a single eye injection of stem cell retinal sheets in adults with retinitis pigmentosa.
Boston, United StatesAlso MinneapolisAge 18+ - Tests BS01, a light-sensitive gene treatment, in people with retinitis pigmentosa
Tests BS01 in adults with retinitis pigmentosa, an inherited eye disease.
Teaneck, United StatesAge 18+ - Tests AGTC-501 gene therapy in males with inherited eye disease
Tests AGTC-501 gene therapy in males with X-linked retinitis pigmentosa, a rare inherited eye disease.
Boston, United StatesAlso Cincinnati, Cleveland, Dallas, Jacksonville, Miami, PortlandAge 12+ - Tests new retinal stimulation devices in people with retinitis pigmentosa
Tests new retinal stimulation methods and training in people with retinitis pigmentosa.
Ann Arbor, United StatesAge 25 to 89 - Testing night vision to measure retinal disease severity
Studies how well people see in the dark to assess retinal disease.
Bethesda, United StatesAge 5 to 100 - Collecting body samples from people with retinal eye diseases and healthy volunteers
Collects hair, skin, saliva, urine or blood from people with retinal diseases and healthy volunteers.
Bethesda, United StatesAge 0 to 120 - Registry and natural history study of inherited retinal diseases caused by rare gene changes
Follows people with inherited retinal disease caused by rare gene variants over time.
Ann Arbor, United StatesAlso Atlanta, Baltimore, Boston, Dallas, Durham, Houston, Jacksonville, Little Rock, …Age 4+ - Registry collecting health information on people with rare diseases
Collects voluntary health information from people with rare or undiagnosed conditions for future research.
Sioux Falls, United States - Screens people with Stargardt disease for future ACDN-01 eye trials
Checks people with Stargardt disease to see if they may join ACDN-01 trials.
Ann Arbor, United StatesAlso Baltimore, Boston, Cincinnati, Dallas, Gainesville, Houston, San FranciscoAge 5+ - Studies how pyrimidine and purine metabolism disorders affect the body
Compares test results from people with these disorders, family members, and healthy people.
Bethesda, United StatesAge 0 to 100 - Tests patients' own bone marrow stem cells for eye and optic nerve diseases
Tests own bone marrow stem cells in adults with retinal or optic nerve disease.
Coral Springs, United StatesAlso WestportAge 18+ - Imaging the Retina in People With Inherited Retinal Degeneration
Studies retina structure and function in people with retinitis pigmentosa using high-resolution eye imaging.
San Francisco, United StatesAge 13+
Where treatment stands
Approved: 1
Officially approved for this disease in the EU, the US, Switzerland or France.
Human testing stage: 5
Being tested in people. Many treatments at this stage are never approved.
Animal testing stage: 4
Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.
Lab research stage: 1
Worked on cells in the lab in a study published in the last 12 months. Most early ideas never reach people.
Placebo: a dummy treatment without the medicine, used for comparison.
Phase 1, 2, 3: the steps of testing in people. Phase 1 checks safety, phase 3 is the last step before approval.
The EU medicines agency (EMA) and its list of medicines in the EU, US prescribing labels (DailyMed, openFDA), the Swiss medicines register (Swissmedic), the French medicines database (ANSM) and the Health Canada drug database, checked on 11 November 2026. Every medicine links to its own official text.
A computer made this list from the official texts: it kept only medicines whose own approval text names the disease, wrote "Who it is for" from that text and checked it against the text a second time. People have not reviewed it yet.
The trials: ClinicalTrials.gov and the EU trials register, as copied into our trial database, checked on 12 November 2026. Every treatment in trials links to its own trial records; the texts are written by AI from them and checked against them by a second AI. People have not reviewed them yet. Placebo, standard medicines used for comparison and procedures are left out.
Phase 3 trials are listed from every country; only some phase 2 trials are listed, so 3 other open phase 2 trials are not listed.
Animal and lab research: studies listed in PubMed and published in the 12 months before 12 November 2026, found by a search for retinitis pigmentosa. AI chose the treatments from the study summaries and wrote the texts; a second AI checked each one against its study summary. People have not reviewed them yet. Treatments already in the approved or human testing lists are left out. A result in animals or cells does not show that a treatment works in people.
Not medical advice. Talk to your doctor before you change any treatment.
The approval records under a medicine come from Drugs@FDA and the FDA labels (openFDA) and from the EU medicines agency’s medicine data, with its orphan designations, checked on 13 Nov 2026. A date is the medicine’s first approval, for any use; the quoted text is its approved use as written today.
Support organisations
Patient organisations and helplines in United States, for you and your family.
Retinitis pigmentosa organisations in United States
- Foundation Fighting Blindness
US nonprofit driving research for inherited retinal diseases such as retinitis pigmentosa and age-related macular degeneration, with patient information.
- Genetic and Rare Diseases Information Center
NIH information center (GARD) providing reliable information on genetic and rare diseases to patients and families via website and contact center.
- Usher Syndrome Coalition
Massachusetts-based coalition serving the Usher syndrome community with information, parent resources, a contact database and research data collection.
General support in United States
- 988 Suicide & Crisis Lifeline
US national 24/7 free and confidential lifeline for anyone in suicidal crisis or emotional distress, reachable by calling or texting 988 or by chat.
- MedlinePlus
Free, easy-to-read health information service of the US National Library of Medicine (NIH) on diseases, conditions, drugs and wellness.
International organisations
Offer tissue or data
There are three ways to help research move faster.
Treatments approved outside the EU
We found no medicine for retinitis pigmentosa approved in the US or Japan that is not approved in the EU. These are the ones approved in the EU.
Checked on 11 Nov 2026 in the official lists of the US (FDA), Japan (PMDA, approvals since April 2004) and the EU (EMA).
Your health insurer may pay part of the cost, sometimes all of it. This depends on your insurer, your plan and the country, so always ask your insurer before you go. For planned care in the EU, the EEA and Switzerland, ask about form S2.
“Miracle cure” fact checker
Social media spreads misinformation. Paste what you read here, and we'll tell you whether there is scientific evidence behind it.
What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.
Before you pay for anything, ask three things
- Is there a published study in people?
- Can I have the full price in writing?
- What does my doctor say?
“Cures” others already fact-checked
- Omega-3 fatty acids (fish oil) & Retinitis pigmentosa
- Curcumin (turmeric) & Retinitis pigmentosa
- Stem cell treatment & Retinitis pigmentosa
- CBD (cannabidiol) & Retinitis pigmentosa
About retinitis pigmentosa
Sources: MedlinePlus, MedlinePlus Genetics
An inherited eye disease that slowly damages the retina, the light-sensing layer at the back of the eye. The first sign is usually a loss of night vision, which may occur in childhood or adolescence. Later, blind spots at the edges of the visual field increase in size until they merge to produce tunnel vision. There is no effective treatment for this condition, but clinical trials are in progress to assess new treatments, including gene therapy. It affects about 1 in 4,000 people in the United States. The disorder will continue to progress slowly, and complete blindness is uncommon.
What is it?
Retinitis pigmentosa is a group of inherited eye diseases that damage the retina. The retina has two kinds of light-sensing cells: rods, for seeing in dim light, and cones, for daylight and colour. In this disease they are slowly lost, usually the rods first. Both eyes are usually affected.
It is the most common inherited disease of the retina, affecting about 1 in 3,500 to 4,000 people in the United States and Europe. Having family members with it is the main risk. Retinitis pigmentosa can have different inheritance patterns depending on the specific gene involved. It can be autosomal dominant (one altered copy of a gene is enough, and most people have an affected parent), autosomal recessive (both copies of a gene must have a variant; the parents each carry one copy), or X-linked (in males one altered copy is typically sufficient; this is not always true for females).
The first signs
Symptoms often first appear in childhood, but severe vision problems do not often develop before early adulthood.
- poor night vision, or trouble finding your way in the dark;
- losing side vision, so it feels like looking through a tunnel;
- sensitivity to bright light;
- later, trouble seeing colours and reading.
How doctors find out
Tests include an exam of the retina by ophthalmoscopy after the pupils have been dilated. The main sign of the disease is the presence of dark deposits in the retina. Other tests check your side vision, sharpness of sight and colour vision, take photos of the retina, and measure the retina's electrical response to light (electroretinogram).
Current treatment
There is no effective treatment for this condition. Sunglasses that protect the retina from ultraviolet light may help preserve vision, a vision specialist can help you adapt to vision loss, and cataracts or retinal swelling found at regular eye checks can be treated.
Will it get worse?
Yes, slowly. The age it starts and how fast it gets worse differ from person to person. Over time, both side and central vision are lost, which makes reading, driving and recognising faces harder. Most people with it become legally blind as adults, but complete blindness is uncommon.
Medicines and supplements: what helps, and what to watch for
There is no effective treatment for this condition.
Good to know:
- sunglasses that block ultraviolet light may help protect the sight you have;
- some studies suggest that treatment with antioxidants (such as high doses of vitamin A palmitate) may slow the disease, but taking high doses of vitamin A can cause serious liver problems, and the benefit of treatment must be weighed against the risks to the liver;
- make regular visits to an eye care specialist, who can detect cataracts or retinal swelling; both of these problems can be treated.
Eye surgery, for some people
People with RP often develop cataracts at an early age. Cataracts can be removed if they contribute to vision loss. Tiny electronic implants for the retina are still at an early stage of development.
Is there a cure?
There is no effective treatment for this condition. Clinical trials are testing gene therapy and supplements such as omega-3 (DHA) and lutein.
Sources
Written in plain words by Frontlight from these pages: